Novel Peptide Therapeutics for Hypertension
高血压的新型肽疗法
基本信息
- 批准号:10077576
- 负责人:
- 金额:$ 61.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-03-15 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAfrican AmericanAldosteroneAnti-Inflammatory AgentsBindingBlood PressureCardiacCardiovascular systemCellsChemical StructureChemosensitizationChronicChronic Kidney FailureClinicClinicalClinical ResearchClinical SciencesCyclic GMPDevelopmentDevicesEndotheliumEngineeringEthnic groupExcretory functionExperimental ModelsFoundationsFutureGeneral PopulationGenerationsGenesGenetic VariationHeart failureHormonesHumanHypertensionImpairmentIn VitroInbred SHR RatsKidneyLeadLigandsMetabolic syndromeMolecular BankNatriuresisNatriuretic PeptidesNeprilysinOrganOutcomeParticulatePathway interactionsPeptidesPharmaceutical PreparationsPropertyReadinessReceptor, Angiotensin, Type 1ReportingResistanceResistant HypertensionRiskSodiumStrokeSubcutaneous InjectionsSystemTestingTimeTranslational ResearchUnited States National Institutes of HealthVasodilationatrial natriuretic factor receptor Ablood pressure reductionblood pressure regulationclinical centercoronary eventdesignhigh riskhigh salt diethigh throughput screeninghuman studyin vivoinnovationnew therapeutic targetnext generationnovelnovel therapeuticspeptide drugpositive allosteric modulatorreceptorrepositoryresponsesmall moleculesmall molecule librariessmall molecule therapeuticssynergism
项目摘要
PROJECT SUMMARY
The objective of this application is to advance novel peptide therapeutics for hypertension with a special
focus on resistant hypertension (RH) for which there are no approved drugs or devices in the US. Our
strategy is to target the particulate guanylyl cyclase receptor-A/cyclic guanosine monophosphate (pGC-
A/cGMP) pathway for which the cardiac hormone ANP is an endogenous ligand. Studies to date support a
key role for the pGC-A/cGMP pathway in blood pressure (BP) regulation. The mechanism of BP lowering is
natriuresis, vasodilation and aldosterone suppression. Beyond BP lowering properties, this pathway also
possesses anti-hypertrophic, anti-fibrotic, anti-inflammatory and endothelial protective actions. In the general
population, we and others have reported a genetic variation of the ANP gene (rs5068) is associated with higher
ANP, lower BP and protection from hypertension (HTN) and metabolic syndrome. We also reported that early
stages of human HTN are characterized by reduced ANP, while severe HTN is characterized by lower ANP
and higher aldosterone. Importantly, African Americans (AAs) represent an ethnic population at high risk for
RH and are characterized by a 40% reduction in circulating natriuretic peptides (NPs) compared to other ethnic
groups. The applicants designed MANP as a best-in-class pGC-A/cGMP activator, which possesses
enhanced pGC-A/cGMP activating properties, and is markedly resistant to degradation by neprilysin. In
experimental models, MANP is superior in lowering BP, enhancing natriuresis and suppressing aldosterone
compared to ANP. In the only human study to date, once daily subcutaneous injection of MANP, for three
days, in subjects with RH was well tolerated, safe and robustly reduced BP, suppressed aldosterone and
enhanced sodium excretion as well as GFR. First, we propose to define the responsiveness to MANP in
African Americans (AAs) with RH. Second, we will define the chronic cardiorenal protective and RAAS
suppressing actions of a next generation MANP (i.e. MANP2) in spontaneously hypertensive rats (SHRs).
Third, we propose to define synergism in vitro between two lead small molecule positive allosteric
modulators (PAMs) with MANP2 to optimize pGC-A activation. Specific Aim 1: Define BP, CV, renal,
neurohumoral, and cGMP responses of MANP in AAs with RH using Mayo Clinic's Center for Clinical and
Translational Science (CCaTS) Clinical Research Unit (CRU). Specific Aim 2: Establish in vivo the chronic
cardiorenal protective and RAAS suppressing properties of MANP2 in SHRs compared to Entresto. Specific
Aim 3: Define synergy in pGC-A/cGMP activation, in vitro, between two lead PAMs and MANP2 in human
primary cells.
项目概要
本申请的目的是推进具有特殊功能的新型肽疗法治疗高血压
重点关注难治性高血压(RH),美国尚无批准的药物或设备。我们的
策略是针对颗粒鸟苷酸环化酶受体-A/环鸟苷单磷酸(pGC-
A/cGMP) 途径,其中心脏激素 ANP 是内源性配体。迄今为止的研究支持
pGC-A/cGMP 通路在血压 (BP) 调节中的关键作用。降血压的机制是
尿钠排泄、血管舒张和醛固酮抑制。除了降血压特性外,该途径还
具有抗肥厚、抗纤维化、抗炎和内皮保护作用。一般来说
人群中,我们和其他人报告了 ANP 基因 (rs5068) 的遗传变异与更高的
ANP、降低血压以及预防高血压 (HTN) 和代谢综合征。我们还报道过早
人类高血压各阶段的特点是 ANP 降低,而重度高血压的特点是 ANP 降低
和较高的醛固酮。重要的是,非裔美国人 (AA) 是一个高风险族群
与其他种族相比,RH 的特点是循环利尿钠肽 (NP) 减少 40%
组。申请人将 MANP 设计为同类最佳的 pGC-A/cGMP 激活剂,具有
增强的 pGC-A/cGMP 激活特性,并且显着抵抗脑啡肽酶的降解。在
实验模型中,MANP在降低血压、增强尿钠和抑制醛固酮方面具有优越性
与ANP相比。在迄今为止唯一的人体研究中,每日一次皮下注射 MANP,连续 3 次
天,在 RH 受试者中,其耐受性良好、安全且大幅降低血压、抑制醛固酮和
增强钠排泄以及 GFR。首先,我们建议定义对 MANP 的响应
具有 RH 的非裔美国人 (AA)。其次,我们将定义慢性心肾保护和RAAS
抑制下一代 MANP(即 MANP2)在自发性高血压大鼠(SHR)中的作用。
第三,我们建议定义两种先导小分子正变构之间的体外协同作用
调节剂 (PAM) 与 MANP2 一起优化 pGC-A 激活。具体目标 1:定义 BP、CV、肾、
使用 Mayo Clinic 临床和治疗中心研究 MANP 在 AA 和 RH 中的神经体液和 cGMP 反应
转化科学 (CCaTS) 临床研究单位 (CRU)。具体目标 2:建立体内慢性
与 Entresto 相比,SHR 中 MANP2 的心肾保护和 RAAS 抑制特性。具体的
目标 3:定义人体中两种主要 PAM 和 MANP2 之间体外 pGC-A/cGMP 激活的协同作用
原代细胞。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension.
- DOI:10.1161/hypertensionaha.121.18837
- 发表时间:2022-04
- 期刊:
- 影响因子:0
- 作者:Dzhoyashvili NA;Iyer SR;Chen HH;Burnett JC Jr
- 通讯作者:Burnett JC Jr
Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation.
血管紧张素II作为Guanylyl环化酶A受体和环状GMP生成的自然现有抑制剂的证据。
- DOI:10.3390/ijms24108547
- 发表时间:2023-05-10
- 期刊:
- 影响因子:5.6
- 作者:Ma, Xiao;Iyer, Seethalakshmi R.;Ma, Xiaoyu;Reginauld, Shawn H.;Chen, Yang;Pan, Shuchong;Zheng, Ye;Moroni, Dante G.;Yu, Yue;Zhang, Lianwen;Cannone, Valentina;Chen, Horng H.;Ferrario, Carlos M.;Sangaralingham, S. Jeson;Burnett Jr, John C.
- 通讯作者:Burnett Jr, John C.
Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators.
发现小分子鸟苷酸环化酶 A 受体正变构调节剂。
- DOI:10.1073/pnas.2109386118
- 发表时间:2021
- 期刊:
- 影响因子:11.1
- 作者:Sangaralingham,SJeson;Whig,Kanupriya;Peddibhotla,Satyamaheshwar;Kirby,RJason;Sessions,HamptonE;Maloney,PatrickR;Hershberger,PaulM;Mose-Yates,Heather;Hood,BeckyL;Vasile,Stefan;Pan,Shuchong;Zheng,Ye;Malany,Siobhan;BurnettJr,
- 通讯作者:BurnettJr,
First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension.
- DOI:10.1161/hypertensionaha.121.17159
- 发表时间:2021-12
- 期刊:
- 影响因子:0
- 作者:Chen HH;Wan SH;Iyer SR;Cannone V;Sangaralingham SJ;Nuetel J;Burnett JC Jr
- 通讯作者:Burnett JC Jr
MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice.
- DOI:10.1161/hypertensionaha.121.18906
- 发表时间:2022-08
- 期刊:
- 影响因子:8.3
- 作者:Chen, Yang;Iyer, Seethalakshmi R.;Nikolaev, Viacheslav O.;Naro, Fabio;Pellegrini, Manuela;Cardarelli, Silvia;Ma, Xiao;Lee, Hon-Chi;Burnett, John C., Jr.
- 通讯作者:Burnett, John C., Jr.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John C Burnett其他文献
cGMP enhancing strategies for acute and chronic heart failure
- DOI:
10.1186/1471-2210-5-s1-s22 - 发表时间:
2005-06-16 - 期刊:
- 影响因子:2.700
- 作者:
John C Burnett;Guido Boerrigter - 通讯作者:
Guido Boerrigter
Integrin receptor subtype antagonism augments BNP-mediated cGMP generation in cultured human cardiac fibroblasts: evidence for particulate guanylate cyclase receptor and integrin receptor cross-talk
- DOI:
10.1186/1471-2210-7-s1-p30 - 发表时间:
2007-07-25 - 期刊:
- 影响因子:2.700
- 作者:
Brenda K Huntley;John C Burnett - 通讯作者:
John C Burnett
Pharmacokinetic and pharmacodynamic study of a novel chimeric natriuretic peptide, CD-NP, in the normal dog
- DOI:
10.1186/1471-2210-7-s1-p38 - 发表时间:
2007-07-25 - 期刊:
- 影响因子:2.700
- 作者:
Candace YW Lee;Guido Boerrigter;Gail J Harty;John C Burnett - 通讯作者:
John C Burnett
Coadministration of B-type natriuretic peptide and the vasopressin-2 receptor antagonist tolvaptan: a novel physiologic strategy to enhance water and sodium excretion without adversely affecting renal or neurohumoral function in experimental congestive heart failure
- DOI:
10.1186/1471-2210-7-s1-p12 - 发表时间:
2007-07-25 - 期刊:
- 影响因子:2.700
- 作者:
Lisa C Costello-Boerrigter;Guido Boerrigter;Gail J Harty;John C Burnett - 通讯作者:
John C Burnett
Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines
- DOI:
10.1186/1471-2210-11-s1-p11 - 发表时间:
2011-08-01 - 期刊:
- 影响因子:2.700
- 作者:
Guido Boerrigter;Lisa C Costello-Boerrigter;Gail J Harty;John C Burnett - 通讯作者:
John C Burnett
John C Burnett的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John C Burnett', 18)}}的其他基金
Novel Peptide Therapeutics for Cardiorenal Protection in Heart Failure
用于心力衰竭心肾保护的新型肽疗法
- 批准号:
9753353 - 财政年份:2017
- 资助金额:
$ 61.49万 - 项目类别:
Novel Peptide Therapeutics for Cardiorenal Protection in Heart Failure
用于心力衰竭心肾保护的新型肽疗法
- 批准号:
9211673 - 财政年份:2017
- 资助金额:
$ 61.49万 - 项目类别:
Protein Therapeutics to Prevent Heart Failure Post Myocardial Infarction
预防心肌梗塞后心力衰竭的蛋白质疗法
- 批准号:
8020951 - 财政年份:2010
- 资助金额:
$ 61.49万 - 项目类别:
Protein Therapeutics to Prevent Heart Failure Post Myocardial Infarction
预防心肌梗塞后心力衰竭的蛋白质疗法
- 批准号:
7867072 - 财政年份:2010
- 资助金额:
$ 61.49万 - 项目类别:
相似海外基金
Broadening Participation Research: Understanding faculty attitudes, competency, and perceptions of providing career advising to African American STEM students at HBCUs
扩大参与研究:了解教师对 HBCU 的非裔美国 STEM 学生提供职业建议的态度、能力和看法
- 批准号:
2306671 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
Continuing Grant
Cognitive Behavioral Faith-based Depression Intervention For African American Adults (CB-FAITH): An Effectiveness And Implementation Trial
非裔美国成年人基于认知行为信仰的抑郁干预 (CB-FAITH):有效性和实施试验
- 批准号:
10714464 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
DELINEATING THE ROLE OF THE HOMOCYSTEINE-FOLATE-THYMIDYLATE SYNTHASE AXIS AND URACIL ACCUMULATION IN AFRICAN AMERICAN PROSTATE TUMORS
描述同型半胱氨酸-叶酸-胸苷酸合成酶轴和尿嘧啶积累在非裔美国人前列腺肿瘤中的作用
- 批准号:
10723833 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness-based Stress Reduction for Justice-Involved Black/African American Female Adolescents and Parents/Caregivers
探索创伤后应激障碍 (PTSD) 症状、障碍和促进因素,为涉及正义的黑人/非裔美国女性青少年和父母/照顾者进行基于正念的减压
- 批准号:
10593806 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
Preventing Firearm Suicide Deaths Among Black/African American Adults
防止黑人/非裔美国成年人因枪支自杀死亡
- 批准号:
10811498 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
BCSER - PVEST: A Dynamic Framework for Investigating STEM Interest, Attitude and Identity Among African American Middle School Students
BCSER - PVEST:调查非裔美国中学生 STEM 兴趣、态度和身份的动态框架
- 批准号:
2327055 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
Standard Grant
Making the Connection: Understanding the dynamic social connections impacting type 2 diabetes management among Black/African American men
建立联系:了解影响黑人/非裔美国男性 2 型糖尿病管理的动态社会联系
- 批准号:
10782674 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
Building a Community-Based Mental Health Literacy Intervention for African American Young Adults
为非裔美国年轻人建立基于社区的心理健康素养干预措施
- 批准号:
10738855 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
African American Literature in "post" Post-Racial America
“后”后种族美国中的非裔美国文学
- 批准号:
23K00376 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Impact of a Race-Based Stress Reduction Intervention on Well-Being, Inflammation, and DNA methylation in Older African American Women at Risk for Cardiometabolic Disease
基于种族的减压干预措施对有心血管代谢疾病风险的老年非洲裔美国女性的健康、炎症和 DNA 甲基化的影响
- 批准号:
10633624 - 财政年份:2023
- 资助金额:
$ 61.49万 - 项目类别:














{{item.name}}会员




